KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $19734.0.

  • Co-Diagnostics' Change in Accured Expenses fell 9675.02% to $19734.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 28900.99%. This contributed to the annual value of $2.2 million for FY2024, which is 2202.78% up from last year.
  • Per Co-Diagnostics' latest filing, its Change in Accured Expenses stood at $19734.0 for Q3 2025, which was down 9675.02% from -$1.7 million recorded in Q2 2025.
  • Co-Diagnostics' Change in Accured Expenses' 5-year high stood at $2.4 million during Q2 2021, with a 5-year trough of -$1.7 million in Q4 2022.
  • Over the past 5 years, Co-Diagnostics' median Change in Accured Expenses value was -$97897.0 (recorded in 2023), while the average stood at -$107944.6.
  • Per our database at Business Quant, Co-Diagnostics' Change in Accured Expenses skyrocketed by 72028.25% in 2024 and then crashed by 1023995.39% in 2025.
  • Quarter analysis of 5 years shows Co-Diagnostics' Change in Accured Expenses stood at -$382432.0 in 2021, then crashed by 339.52% to -$1.7 million in 2022, then soared by 124.51% to $411996.0 in 2023, then skyrocketed by 353.73% to $1.9 million in 2024, then tumbled by 98.94% to $19734.0 in 2025.
  • Its Change in Accured Expenses was $19734.0 in Q3 2025, compared to -$1.7 million in Q2 2025 and -$1.6 million in Q1 2025.